Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The antibody was designed and developed at Abzena’s Cambridge, UK,
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Upgrades 2025 full-year CDMO sales and margin outlook
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Subscribe To Our Newsletter & Stay Updated
